Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can tacrolimus replace ciclosporin and prednisone to treat myasthenia gravis?

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Palace J et al. (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50: 1778–1783

    Article  CAS  Google Scholar 

  2. Tindall RS et al. (1993) A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 681: 539–551

    Article  CAS  Google Scholar 

  3. Konishi T et al. (2005) Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry 76: 448–450

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Christine Kyme, Assistant Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John Newsom-Davis.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Newsom-Davis, J. Can tacrolimus replace ciclosporin and prednisone to treat myasthenia gravis?. Nat Rev Neurol 1, 14–15 (2005). https://doi.org/10.1038/ncpneuro0038

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0038

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing